BRIEF-Xenetic Biosciences receives update from Shire's Phase 1/2 study evaluating SHP656 in development as long-acting treatment for Hemophilia A

* Xenetic Biosciences - receives program update from partner Shire's phase 1/2 study evaluating SHP656 in development as a long-acting treatment for Hemophilia A
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.